Change of venue with more capacity, and open for new registration
This event is very popular. If any company is interested in sponsoring, please contact firstname.lastname@example.org.
Please register online. Online registration is free and will be closed when the limit is reached. After that you will be put on a waiting list. Onsite registration is $10.
1:30-2:00PM check-in, onsite registration and networking
1. Personalized health care for oncology by Craig Cummings, Associate Director, Oncology Biomarker Development, Genentech
2. NGS application in immunology studies by Naibo Yang, Director, Immunogenetics, Complete Genomics Inc.
The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy
In the 15 years since the publication of the draft human genome, sequencing technologies have advanced rapidly and the cost to sequence a genome has dropped precipitously from several billion dollars down to several thousand dollars. NGS now enables analysis of a large number of DNA bases in a cost- and time-effective manner. In recent years, this promising technology has been transferred to clinical diagnostics in oncology with the aim to better define which therapy should be given in each patient. The aim of this tutorial is to review next-generation sequencing (NGS) techniques and the emerging role of this technology in the diagnosis and treatment of cancer. I will provide a basic overview of the different types of NGS and the strengths and weaknesses of each approach in the context of cancer as a heterogeneous disease driven by DNA-altering mutations. Finally, I will discuss how this information can inform personalized clinical development of targeted therapies.
[Review article is available online at http://onlinelibrary.wiley.com/doi/10.1111/cts.12429/full]
Craig Cummings, PhD
Associate Director, Oncology Biomarker Development
Genentech, a Member of the Roche Group
Dr. Craig Cummings received his PhD in Genetics and pursued a postdoctoral fellowship in Microbiology and Immunology at the Stanford University School of Medicine. He is currently Associate Director of Data Science in the Genentech Department of Oncology Biomarker Development, where his group is responsible for biomarker data management, analysis, and development—in collaboration with Foundation Medicine—of NGS-based methods for cancer immunotherapy diagnostics. Prior to joining Genentech, he contributed to development of next-generation sequencing platforms, tools, and diagnostic tests at Applied Biosystems/Life Technologies and Sequenta, Inc.
High Throughput Sequencing and Its Applications on Immunology
High Throughput Sequencing is rapidly penetrating all aspects of biological research, from genomics, genetics to oncology, immunology, aging, general health management etc. Complete Genomics Inc, as a BGI company, is focusing on high throughput sequencing technologies and its applications. Within this large scope, my team studies the immune system with NGS technology. The total collection of immunoglobulin molecules (BCRs or antibodies) and TCRs are collectively called immune repertoires. They are ideal subjects for NGS studies. Through a single sequencing study, millions of unique antibody and TCR sequences could be obtained. Their status is important to one’s health. And their responses are key components of body’s fighting against diseases, regardless dealing with invading pathogens or cancer.
This talk will mainly focus on NGS and its applications in immunology field. It will cover topics of immune system and health, immune repertoire studies through NGS , antibody discovery research and cancer immune therapy etc.
Naibo Yang, PhD
Director of Immunogenetics
Complete Genomics Inc ( A BGI company)
BIO: Dr. Naibo Yang received his PhD in Physiology from Thomas Jefferson University and got his postdoc training at Stanford University. He is currently carrying on his research at both Complete Genomics (Mountain View) and BGI headquarter (Shenzhen), as the Director of Immunogenetics. His research is focusing on NGS applications in immunology and novel antibody discovery technologies. Prior to Complete Genomics, Dr. Yang had extensive experience in drug discovery and diagnostics. He was a major contributor to discovery research at Exelixis Inc and Affymax Inc, in the fields of oncology and blood disease related therapeutics. Besides his scientific research activities, Dr. Yang is also a longtime contributor and supporter of CABS.
everyone – $0 (USD) - 28 left